|De novo design of potent and selective mimics of IL-2 and IL-15|
DA Silva, S Yu, UY Ulge, JB Spangler, KM Jude, C Lab„o-Almeida, LR Ali, ...
Nature 565 (7738), 186-191, 2019
|Insights into cytokine–receptor interactions from cytokine engineering|
JB Spangler, I Moraga, JL Mendoza, KC Garcia
Annual review of immunology 33, 139, 2015
|Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling|
JB Spangler, JR Neil, S Abramovitch, Y Yarden, FM White, ...
Proceedings of the National Academy of Sciences 107 (30), 13252-13257, 2010
|Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms|
JB Spangler, J Tomala, VC Luca, KM Jude, S Dong, AM Ring, P Votavova, ...
Immunity 42 (5), 815-825, 2015
|Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps|
S Mitra, AM Ring, S Amarnath, JB Spangler, P Li, W Ju, S Fischer, J Oh, ...
Immunity 42 (5), 826-838, 2015
|Multifarious determinants of cytokine receptor signaling specificity|
I Moraga, J Spangler, JL Mendoza, KC Garcia
Advances in immunology 121, 1-39, 2014
|Engineered proteins including mutant fibronectin domains|
KD Wittrup, JB Spangler, BJ Hackel
US Patent App. 13/390,086, 2012
|Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers|
I Moraga, JB Spangler, JL Mendoza, M Gakovic, TS Wehrman, P Krutzik, ...
Elife 6, e22882, 2017
|Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression|
JB Spangler, MT Manzari, EK Rosalia, TF Chen, KD Wittrup
Journal of molecular biology 422 (4), 532-544, 2012
|Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers|
M You, J Spangler, E Li, X Han, P Ghosh, K Hristova
Biochemistry 46 (39), 11039-11046, 2007
|Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications|
T Iwamoto, M You, E Li, J Spangler, JM Tomich, K Hristova
Biochimica et Biophysica Acta (BBA)-Biomembranes 1668 (2), 240-247, 2005
|Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy|
JB Spangler, E Trotta, J Tomala, A Peck, TA Young, CS Savvides, ...
The Journal of Immunology 201 (7), 2094-2106, 2018
|IgM autoantibodies recognizing ACE2 are associated with severe COVID-19|
L Casciola-Rosen, DR Thiemann, F Andrade, MIT Zambrano, JE Hooper, ...
|Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells|
CR Glassman, YK Mathiharan, KM Jude, L Su, O Panova, PJ Lupardus, ...
Cell 184 (4), 983-999. e24, 2021
|Targeting cancer metastasis with antibody therapeutics|
H Yang, YH Kuo, ZI Smith, J Spangler
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 13 (4†…, 2021
|A strategy for the selection of monovalent antibodies that span protein dimer interfaces|
JB Spangler, I Moraga, KM Jude, CS Savvides, KC Garcia
Journal of Biological Chemistry 294 (38), 13876-13886, 2019
|Suspendable hydrogel nanovials for massively parallel single-cell functional analysis and sorting|
J De Rutte, R Dimatteo, MM Archang, M Van Zee, D Koo, S Lee, ...
ACS nano, 2022
|Reprogramming immune proteins as therapeutics using molecular engineering|
R Kureshi, M Bahri, JB Spangler
Current opinion in chemical engineering 19, 27-34, 2018
|A suspension cell‐based interaction platform for interrogation of membrane proteins|
PJ Krohl, KB Kim, L Lew, D VanDyke, SD Ludwig, JB Spangler
AIChE Journal 66 (12), e16995, 2020
|Emerging technologies in protein interface engineering for biomedical applications|
PJ Krohl, SD Ludwig, JB Spangler
Current opinion in biotechnology 60, 82-88, 2019